HOME
MARKET
TRADE
PRICING
PLATFORM
HELP
LOG IN
Hearing Oppenheimer Initiates Coverage On NeuBase Therapeutics With An Outperform Rating, $14 Price Target
Benzinga · 11/20/2019 21:15
Related